MXCT

Fundamental assessment of MaxCyte (MXCT) is challenging, with a composite score of 2.4/10. Key weaknesses include a low Profit-MV (0.46) and Cash-MV (-0.07), both in lower quartiles, while Asset-MV (-0.50) also drags performance. Inventory and current-assets turnover ratios are sub-optimal, and the Net profit / Total profit ratio at 100% may reflect data quirks rather than true efficiency. Although Gross profit margin is high at 82.07%, it is insufficient to offset other deficits. Historical back-tests show modest one-month returns (e.g., 7.79% for Profit-MV but only 15.13% for Asset-MV), indicating limited reliability. The overall fundamental outlook is therefore negative, warranting caution.